glpg3667
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 18, 2019 (NCT04097938)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TYK2INHIBITOR
TYK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05856448 | Phase 2 | Jun 28, 2023 | Galapagos NV |
| NCT05695950 | Phase 2 | Feb 27, 2023 | Galapagos NV |
| NCT05335447 | Phase 1 | Apr 19, 2022 | Galapagos NV |
| NCT05272683 | Phase 1 | Feb 28, 2022 | Galapagos NV |
| NCT04976270 | Phase 1 | Jul 20, 2021 | Galapagos NV |
| NCT04736927 | Phase 1 | Jan 15, 2021 | Galapagos NV |
| NCT04594928 | Phase 1 | Oct 19, 2020 | Galapagos NV |
| NCT04097938 | Phase 1 | Sep 18, 2019 | Galapagos NV |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 8 | 8 | 2 | 2019 |
1 organizations
Page 1 / 1